Inventor
DIX DANIEL B
US23 patents
⚠️ This page may combine multiple inventors who share the name “DIX DANIEL B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
20 patentsUS9580489B2Feb 28, 2017
VEGF antagonist formulations suitable for intravitreal administration
REGENERON PHARMA67 citations99
US10406226B2Sep 10, 2019
Method of manufacturing VEGF antagonist fusion proteins
REGENERON PHARMA70 citations98
US9636400B2May 2, 2017
VEGF specific fusion protein antagonist formulations
REGENERON PHARMA59 citations97
US10435473B2Oct 8, 2019
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
REGENERON PHARMA18 citations93
US9238692B2Jan 19, 2016
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
REGENERON PHARMA26 citations93
US10857231B2Dec 8, 2020
Formulations of VEG antagonist fusion proteins and method of manufacturing them
REGENERON PHARMA9 citations92
US10472425B2Nov 12, 2019
Stabilized formulations containing anti-PCSK9 antibodies
REGENERON PHARMA12 citations92
US9193801B2Nov 24, 2015
Stabilized formulations containing anti-PCSK9 antibodies
REGENERON PHARMA25 citations92
US10072086B2Sep 11, 2018
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
REGENERON PHARMA12 citations91
US10752701B2Aug 25, 2020
Stabilized formulations containing anti-PCSK9 antibodies
REGENERON PHARMA8 citations83
US11806398B2Nov 7, 2023
Citrate buffered VEGF antagonist formulations
REGENERON PHARMA1 citations73
US11926670B2Mar 12, 2024
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
REGENERON PHARMA1 citations72
US11098127B2Aug 24, 2021
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
REGENERON PHARMA1 citations72
US11059896B2Jul 13, 2021
Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies
REGENERON PHARMA3 citations72
US12440622B2Oct 14, 2025
Devices and methods for overfilling drug containers
REGENERON PHARMA0 citations62
US11918785B2Mar 5, 2024
Devices and methods for overfilling drug containers
REGENERON PHARMA0 citations62
US11673967B2Jun 13, 2023
Stabilized formulations containing anti-PCSK9 antibodies
REGENERON PHARMA0 citations62
US11577025B2Feb 14, 2023
Devices and methods for overfilling drug containers
REGENERON PHARMA0 citations62
US12077593B2Sep 3, 2024
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
REGENERON PHARMA0 citations61
US12070502B2Aug 27, 2024
Process for reducing subvisible particles in a pharmaceutical formulation
REGENERON PHARMA0 citations60